Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098142 | 1.00 | JAK3 (0.49) | JAK3NOTUMJAK2HPGDSTTBK1 | |
| SCHEMBL20548838 | 1.00 | JAK3 (0.49) | JAK3NOTUMJAK2HPGDSTTBK1 | |
| SCHEMBL30882147 | 1.00 | JAK3 (0.49) | JAK3NOTUMJAK2HPGDSTTBK1 | |
| SCHEMBL28812137 | 0.76 | JAK3 (0.60) | JAK3NOTUMJAK2TTBK1TTBK2 | |
| SCHEMBL28249736 | 0.76 | JAK3 (0.47) | JAK3NOTUMJAK2TTBK1TTBK2 | |
| SCHEMBL18599351 | 0.75 | JAK3 (0.46) | JAK3NOTUMJAK2HPGDSTTBK1 | |
| SCHEMBL3491733 | 0.75 | JAK3 (0.59) | JAK3NOTUMJAK2CYP2C9 | |
| Hydrochloric Acid SCHEMBL27966051 | 0.75 | JAK3 (0.59) | JAK3NOTUMJAK2TTBK1TTBK2 | |
| SCHEMBL2606612 | 0.75 | JAK3 (0.59) | JAK3NOTUMJAK2CYP2C9 | |
| Hydrochloric Acid SCHEMBL28120811 | 0.73 | JAK3 (0.57) | JAK3NOTUMJAK2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317946-A | Processes and intermediates for the preparation of baratinib | 因赛特公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4370504-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117043152-A | Methods and intermediates for preparing JAK1 inhibitors | 因赛特公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116761792-A | Methods and intermediates for preparing JAK inhibitors | 因赛特公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4200278-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4200300-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023288197-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022040180-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040172-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398952-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562904-B2 | Synthesis process of ruxolitinib | JAK3, JAK1, JAK2 | JAK3 1/4885NOTUM 1479/4885JAK2 3/4885 |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | JAK3, JAK1, JAK2 | JAK3 1/4885NOTUM 1479/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.